2.50
Hdl Handle:
http://hdl.handle.net/10541/71226
Title:
Immunology and immunotherapy approaches for prostate cancer
Authors:
Elkord, Eyad
Abstract:
Several mechanisms that impair the immune response to promote tumour progression are reported. These mechanisms aim to reduce the ability of antigen-presenting cells to present antigen and activate naïve T cells to support an active immune response or to create a suppressive environment that induce non-functional tumour-associated antigen-specific T cells. Prostate cancer (PC) alone accounts for 33% of incident cancer cases and about 9% of all cancer-related deaths among men in the USA during 2006. Whereas androgen deprivation has remained the first line of therapy for advanced PC, other therapies are still required due to progression to an androgen-resistant state and eventually loss of control in patients receiving hormonal therapy. Immunotherapy seems to be a promising approach to enhance tumour-specific T-cell responses in different cancers including prostate. More importantly, clinical trials in advanced PC patients have shown that immunotherapy may generate significant clinical responses. Immunology and immunotherapy aspects of PC with focus on prostate-specific antigen will be presented.
Affiliation:
CRUK Immunology Department, Paterson Institute for Cancer Research, University of Manchester, Manchester, UK. eelkord@picr.man.ac.uk
Citation:
Immunology and immunotherapy approaches for prostate cancer. 2007, 10 (3):224-36 Prostate Cancer Prostatic Dis.
Journal:
Prostate Cancer and Prostatic Diseases
Issue Date:
2007
URI:
http://hdl.handle.net/10541/71226
DOI:
10.1038/sj.pcan.4500964
PubMed ID:
17420764
Type:
Article
Language:
en
ISSN:
1365-7852
Appears in Collections:
All Paterson Institute for Cancer Research

Full metadata record

DC FieldValue Language
dc.contributor.authorElkord, Eyad-
dc.date.accessioned2009-06-23T11:39:32Z-
dc.date.available2009-06-23T11:39:32Z-
dc.date.issued2007-
dc.identifier.citationImmunology and immunotherapy approaches for prostate cancer. 2007, 10 (3):224-36 Prostate Cancer Prostatic Dis.en
dc.identifier.issn1365-7852-
dc.identifier.pmid17420764-
dc.identifier.doi10.1038/sj.pcan.4500964-
dc.identifier.urihttp://hdl.handle.net/10541/71226-
dc.description.abstractSeveral mechanisms that impair the immune response to promote tumour progression are reported. These mechanisms aim to reduce the ability of antigen-presenting cells to present antigen and activate naïve T cells to support an active immune response or to create a suppressive environment that induce non-functional tumour-associated antigen-specific T cells. Prostate cancer (PC) alone accounts for 33% of incident cancer cases and about 9% of all cancer-related deaths among men in the USA during 2006. Whereas androgen deprivation has remained the first line of therapy for advanced PC, other therapies are still required due to progression to an androgen-resistant state and eventually loss of control in patients receiving hormonal therapy. Immunotherapy seems to be a promising approach to enhance tumour-specific T-cell responses in different cancers including prostate. More importantly, clinical trials in advanced PC patients have shown that immunotherapy may generate significant clinical responses. Immunology and immunotherapy aspects of PC with focus on prostate-specific antigen will be presented.en
dc.language.isoenen
dc.subjectProstate Canceren
dc.subjectTumour Escapeen
dc.subject.meshAnimals-
dc.subject.meshClinical Trials as Topic-
dc.subject.meshDendritic Cells-
dc.subject.meshHumans-
dc.subject.meshImmunotherapy-
dc.subject.meshLymphocyte Activation-
dc.subject.meshMale-
dc.subject.meshProstatic Neoplasms-
dc.subject.meshT-Lymphocytes-
dc.subject.meshTumor Escape-
dc.titleImmunology and immunotherapy approaches for prostate canceren
dc.typeArticleen
dc.contributor.departmentCRUK Immunology Department, Paterson Institute for Cancer Research, University of Manchester, Manchester, UK. eelkord@picr.man.ac.uken
dc.identifier.journalProstate Cancer and Prostatic Diseasesen

Related articles on PubMed

All Items in Christie are protected by copyright, with all rights reserved, unless otherwise indicated.